Last reviewed · How we verify

Oxymetazoline HCL Cream 1.0% — Competitive Intelligence Brief

Oxymetazoline HCL Cream 1.0% (Oxymetazoline HCL Cream 1.0%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist. Area: Dermatology.

marketed Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Oxymetazoline HCL Cream 1.0% (Oxymetazoline HCL Cream 1.0%) — Allergan. Oxymetazoline is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the skin, reducing redness and flushing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Oxymetazoline HCL Cream 1.0% TARGET Oxymetazoline HCL Cream 1.0% Allergan marketed Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor
Comparator: carvedilol Comparator: carvedilol Organon and Co marketed Beta-blocker with alpha-1 antagonist activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Doxazosin mysylate GITS Doxazosin mysylate GITS Pfizer's Upjohn has merged with Mylan to form Viatris Inc. marketed Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor
Placebo to Prazosin Placebo to Prazosin Brian J Lipworth marketed Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor
placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan Montefiore Medical Center marketed Combination cold and cough remedy H1 receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); sigma-1 receptor and NMDA receptor (dextromethorphan)
Norepinephrine (Levophed) Norepinephrine (Levophed) University of Louisville marketed Catecholamine; sympathomimetic amine Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
Cyclopentolate+tropicamide+phenylephrine Cyclopentolate+tropicamide+phenylephrine Pontificia Universidad Catolica de Chile marketed Anticholinergic + sympathomimetic combination Muscarinic acetylcholine receptors (M1-M5); alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist class)

  1. Allergan · 2 drugs in this class
  2. EMS · 1 drug in this class
  3. Institute of Liver and Biliary Sciences, India · 1 drug in this class
  4. Medical University of Graz · 1 drug in this class
  5. Rawalpindi Medical College · 1 drug in this class
  6. Tehran Heart Center · 1 drug in this class
  7. Actavis Inc. · 1 drug in this class
  8. University Tunis El Manar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxymetazoline HCL Cream 1.0% — Competitive Intelligence Brief. https://druglandscape.com/ci/oxymetazoline-hcl-cream-1-0. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: